• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Piramal Pharma Solutions New API Plant in Canada Now Online

    MG America Appoints Claudio Radossi as President

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Sartorius Expands Manufacturing Site in Tunisia

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Piramal Pharma Solutions New API Plant in Canada Now Online

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Grand Opening of Kodiak Sciences’ Bioconjugation Facility

    Vertex Expands Cell and Gene Therapy Footprint
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment

    WCG Appoints Sam Srivastava CEO

    AffyXell Expands Manufacturing Partnership with GenScript ProBio

    ABL and Odimma Therapeutics Enter Development Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Qosina

    Quotient Sciences

    CMC Pharmaceuticals

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Qosina

    Quotient Sciences

    CMC Pharmaceuticals

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    CMOs Facing Significant Capacity Constraints

    Downstream purification creating chronic problems

    Related CONTENT
    • Outsourcing the Manufacture of Clinical Trial APIs
    • CDMO Market Trends & Opportunities
    • Vetio Animal Health
    • Current Trends in Analytical Testing
    • CMOs & Biosimilars Mfg. in the U.S.
    Eric S. Langer, BioPlan Associates06.02.15
    Outsourcing of biomanufacturing has been on the rise in recent years; one measure of success among contract manufacturing organizations (CMOs) is their ability to ensure their facilities keep up with demand. CMO constraints are not necessarily an unhealthy indicator, but must be balanced against clients’ need for access to flexible scheduling, and capacity. In fact, results from BioPlan Associates’ newly-released 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production1 show that CMOs are facing capacity constraints to a more significant degree than in recent years, all while operating at high levels of capacity. And while perceptions of future capacity constraints are more optimistic, CMOs clearly believe that, among a broad swath of improvements they will be implementing, improving their downstream purification technologies will be paramount to overcoming bottleneck challenges.

    What the Data Show
    In our annual global study of 237 biopharmaceutical manufacturers and CMOs, a surprisingly high 36% of CMOs believe their facility is experiencing at least “significant” production capacity constraints today. And if we include those experiencing at least “moderate” constraints, roughly half of CMOs today are experiencing real capacity problems.

    The data show some interesting trends when compared with last year’s results. Although last year about the same percentage of CMOs surveyed were experiencing at least “moderate” constraints, far more are finding constraints are worsening. This year almost twice as many report significant constraints (32.7% vs. 17.4% in 2014).

    Unhealthy Capacity Utilization
    Capacity constraints aren’t always a negative for CMOs, as many presume future growth is based on increasing demand. Further, when properly managed, constraints can be an indicator of efficiency, but must be balanced against clients’ need for access to flexible capacity. 

    On the other hand, this year’s survey results show CMOs may be hitting limits of what would be considered a healthy level of excess (flex) capacity. This is particularly the case for mammalian cell culture—the dominant paradigm—for which CMO respondents this year estimated currently operating at an average 82% of operating capacity. This is a hefty increase from last year’s average of 58% capacity utilization. The last time we saw levels in this range were 10 years ago during what was often referred to as an industry-wide capacity crunch.

    Likewise, CMOs this year estimate operating at around 68% of microbial fermentation capacity, up from last year’s 54%. With CMOs operating at significantly higher levels of capacity this year than last, it’s easy to see why perceptions of capacity constraints are also trending up. 

    Future Capacity Constraints
    Even so, it’s encouraging to see that CMO respondents to this year’s study are less likely to perceive significant capacity constraints in the medium-term than they are to be experiencing them today. Compared to the 36% experiencing significant or severe constraints today, only 1 in 5 are expecting that level of bottlenecks in 2020—essentially, CMOs are confident of their ability to manage capacity problems in the future.

    Overall, our data indicates that about 8 in 10 CMOs expect to face some level of capacity constraint at their facility within 5 years’ time, down from roughly 9 in 10 last year. Along with that, fewer respondents this year expect severe or significant constraints in 5 years than did last year.

    CMOs Spending on Expanding Facilities
    Although CMOs this year are concerned about their current situation, they are more positive about their ability to handle future capacity constraint problems. This may be a reflection of anticipated spending on new facility construction: About 7 in 10 CMOs plan to increase their spending on new facilities this year, and the overall level of budget increases outpace expected spending hikes in many other areas, including staff hiring, process development, and new technologies for upstream and downstream production.

    Moreover, CMOs this year estimate expanding their mammalian cell culture capacity by a substantial 77% over the next 5 years, double the overall amount of expansion (39%) they had forecast last year. Clearly, these organizations seeing that they are operating at high levels of mammalian production capacity today forecast expansions in the future that will ease their constraints.
    CMOs may also be considering the current climate, in which, in contrast to the blockbuster approvals of the early 2000s, most of the current and upcoming drug approvals are for niche products with inherent smaller markets, additional indications of therapy on existing products, new countries, for sub-$1b markets, or for biosimilars/biogenerics production.

    While the onset of biosimilars and biogenerics production is likely to favor CMOs, many of the new products in the pipeline can be absorbed into biomanufacturers’ existing facilities, as the manufacturing volumes are smaller. For biomanufacturers, whose expected future constraints are more moderate in nature than CMOs, there is less alarm, as there are now more options for retrofitting existing facilities to add incremental facility in a relatively short amount of time. And the option for outsourcing will of course continue to be attractive, too.

    Avoiding Constraints
    As part of our ongoing trend analysis of the causes—and potential alleviators—of capacity constraints, we asked CMOs to evaluate the factors likely to create production capacity constraints at their facility over the next 5 years.

    CMOs were most likely to report facility constraints (68%, up from 56% in 2014) as the source of capacity constraints, with this factor consistently atop the rankings over the past several years. In an interesting divergence from last year’s results, however, the physical capacity of downstream purification equipment was the factor second-most likely to be fingered as a culprit by CMOs. This factor was cited by a majority (53%) of respondents this year, up from 37% last year. That’s an important indicator, given improvements in purification technology that suppliers are investing in to move the industry away from such problems, including:
    • Moving bed technologies;
    • Fast-flow resins;
    • Greater binding capacity resins;
    • Membrane separation technologies;
    • Better UF-membranes; and
    • More single-use equipment for purification.
    With CMOs often at the forefront of new technology adoption, it’s a telling indicator that a large proportion would see physical equipment constraints being a source of capacity bottlenecks in 5 years’ time. It may be that CMOs are pessimistic about the potential for truly novel DSP solutions to arrive that will dramatically improve their downstream processing. Although there are promising new technologies that could allow continuous or semi-continuous modes of operation, that could, in turn allowing for a large jump in the titers processed by downstream operations, the timeline for adoption may be longer than 5 years. On the other hand, it’s possible that respondents are reflecting more on their current situation, in which downstream equipment has failed to match upstream improvements in recent years. Indeed, almost two-thirds (64%) of CMOs say that downstream processing is impacting capacity and overall production either by producing some (36%) or serious (27%) bottlenecks today.

    Beyond facility and downstream equipment constraints, CMOs also see staffing problems as contributing to future capacity constraints, with many pointing to an:
    • Inability to retain experienced technical and production staff (42%);
    • Inability to hire new, experienced technical and production staff (37%); and an
    • Inability to hire new, experienced scientific staff (32%).
    One of the primary reasons these hiring problems are expanding, and why staffing is so important, is that much of the knowledge in the biotech community is institutional in nature, and experienced operators help mitigate very costly problems, like contamination risks, because they provide a depth of production experience that reduces costs and cycle times. Part of this trend is simply the on-going 14% growth rate in the biopharma industry. In addition, the move by larger companies to expand into overseas markets is drawing skilled workers as ‘expats’ in these facilities. Although many still consider biotech to be an emerging industry, today, older workers who have ridden the wave of success of in biotech, and are retiring early, or working as experienced consultants. 
    Unlike many other industries, biopharmaceutical manufacturing requires industry-specific experience around regulatory aspects, process variability, and high service level requirements. This makes it difficult to employ workers directly from related industries like chemical processing, food & beverage, etc. without significant additional (re)training.

    Over the next 3-5 years, we expect to see experienced staff—especially those involved in operations and late-stage process development—become more sought after as the industry shifts to lower-cost manufacturing of biosimilars and other products in which flexibility and speed are especially important. Competition that will come about with the advent of biosimilars may cause biomanufacturers and CMOs to be less open about sharing best practices, leading them to place more importance on retaining key technical staff to at least prevent loss of knowledge to competitors.

    From our study, the inability to hire and retain experienced staff appears to be more of a concern for CMOs than for biomanufacturers. Not surprisingly, then, CMOs are also more likely to emphasize training and education as important areas to address in order to avoid significant capacity constraints. Compared to biomanufacturers, CMOs are more likely to see a pressing need to increase training and education in production, technical and regulatory areas, although there is less of a gap in the perceived need for training in scientific areas.

    Even so, in the near-term, CMOs are most likely to push for the development of better downstream purification technologies to avoid future constraints. That’s to be expected, given that physical equipment constraints are a leading reason they expect those future bottlenecks. Single-use products are in high regard, with a significant portion of CMOs seeing the development of most cost-effective and/or better-performing single-use products as helping them avoid future constraints.

    For the most part, CMOs and biomanufacturers are in agreement about the important areas to address in order to avoid future constraints, although in some instances there are some notable gaps between the two groups. According to our data, for example:
    • CMOs are more likely to see the value in establishing manufacturing standards and industry benchmarks, as well as the aforementioned training and education efforts; while
    • Biomanufacturers are more apt to feel the industry should develop more “modularized” production systems and fund more research to maximize production efficiencies.
    In general, the areas in which biomanufacturers felt more strongly were related more to platforms and investments, focusing on reducing scale-up costs and improving yields to lower costs and time to manufacture. By contrast, CMOs displayed more of a staffing and education focus, presumably as a result of a tighter focus on operations within existing facilities.

    Conclusion
    Our data indicates that a significant portion of CMOs, compared to biopharma companies, are experiencing capacity constraints today, perhaps as mammalian cell culture production capacity utilization rates trend higher. Although CMOs are increasing their new facility budgets, and data indicates that their mammalian cell culture capacity continues to grow year after year, one of the key culprits remains limitations with downstream purification, for which CMOs continue to seek improvements.

    Newer and more efficient single-use products could help; this is in keeping with the general shift from blockbuster manufacture to manufacture of multiple niche products, but also is more generally suited to the CMO model, which involves juggling multiple products, platforms and processes. In fact, when we separately asked the industry to identify which new product development areas are of interest to them, the leading area for CMOs was disposable purification products, cited by almost half. Not far behind, chromatography products also rated highly, reflecting CMOs’ desire for more efficient downstream purification technologies.

    Finally, while it’s easy to get caught up in talk of innovation, CMOs are also wary about staffing issues contributing to constraints in the medium-term. Training and educating key technical and operations staff will become more important to CMOs, as will retaining existing staff. After all, sophisticated process equipment needs sophisticated operators.


    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com  301-921-5979.  www.bioplanassociates.com
    Related Searches
    • CMO
    • Development
    • Biomanufacturing
    • Biopharma
    Suggested For You
    Outsourcing the Manufacture of Clinical Trial APIs Outsourcing the Manufacture of Clinical Trial APIs
    CDMO Market Trends & Opportunities CDMO Market Trends & Opportunities
    Vetio Animal Health Vetio Animal Health
    Current Trends in Analytical Testing Current Trends in Analytical Testing
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges
    Year-End Trends in Biopharma Contract Manufacturing Year-End Trends in Biopharma Contract Manufacturing
    Economics of In-House  Buffer Preparation Economics of In-House Buffer Preparation
    2015 in Review: 6 Key Trends Affecting CMOs 2015 in Review: 6 Key Trends Affecting CMOs
    Top 15 Trends in Biopharmaceutical Manufacturing Top 15 Trends in Biopharmaceutical Manufacturing
    Top 15 Trends in Biopharmaceutical Manufacturing Top 15 Trends in Biopharmaceutical Manufacturing
    Bio-CMO Capacity Constraints Bio-CMO Capacity Constraints
    Future Bio-Capacity Constraints Future Bio-Capacity Constraints
    Capacity Utilization Capacity Utilization
    Capacity Utilization Capacity Utilization

    Related Content

    • APIs | Clinical Trial Materials
      Outsourcing the Manufacture of Clinical Trial APIs

      Outsourcing the Manufacture of Clinical Trial APIs

      What to consider when deciding to partner with a CDMO for manufacturing.
      Josh Hoerner, General Manager, Purisys 09.09.21

    • CDMO Market Trends & Opportunities

      CDMO Market Trends & Opportunities

      CDMOs have been some of the biggest winners from COVID contracts and will see benefits for several more years to come. A Q&A with GlobalData’s Peter Shapiro.
      Tim Wright, Editor, Contract Pharma 05.05.21

    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19


    • Bioanalytical Services
      Current Trends in Analytical Testing

      Current Trends in Analytical Testing

      Improved analytical methods continues to be a current need for nearly every aspect of biopharma manufacturing
      Eric S. Langer, BioPlan Associates 05.09.17

    • Biosimilars
      CMOs & Biosimilars Mfg. in the U.S.

      CMOs & Biosimilars Mfg. in the U.S.

      Biosimilars are moving from novel opportunity to mainstream product
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17

      Trending
      • Cellipont Bioservices Expands Cell Therapy Facility | Contract Pharma
      • Biopharma Manufacturing Facility Construction | Contract Pharma
      • Next-Gen Lab Services | Contract Pharma
      • Pharma Development & Manufacturing Trends | Contract Pharma
      • Reviving Local Production Of Antibiotic Powders | Contract Pharma
      Breaking News
      • Piramal Pharma Solutions New API Plant in Canada Now Online
      • MG America Appoints Claudio Radossi as President
      • Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      • Sartorius Expands Manufacturing Site in Tunisia
      • BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      What Are You Reading?
      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 21
      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      P&G Closes HQ Due To Security Threat, Launches New Hair Care Line
      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Brook + Whittle's new acquisition, SunDance goes to HP and more
      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Weekly Recap: Kimberly-Clark to Expand Diaper, Wipes Production in Brazil; The Honest Company to Sell Diapers, Wipes at Walmart & More
      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most Read Stories This Week—May 21
      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login